Literature DB >> 7650690

Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.

M I Dawson1, L Jong, P D Hobbs, J F Cameron, W R Chao, M Pfahl, M O Lee, B Shroot, M Pfahl.   

Abstract

The natural retinoid 9-cis-retinoic acid is an activating ligand for both the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which are members of the retinoid/thyroid hormone/steroid hormone family of nuclear receptor proteins that activate gene transcription through specific response elements. The pharmacophoric groups necessary to confer RXR selectivity were established by evaluating the ability of 21 conformationally restricted retinoids to activate the TREpal retinoic acid receptor response element for gene transcription in the presence of one of the three RAR subtypes or RXR alpha. In contrast to those retinoids selective for the RARs, these RXR-selective retinoids have one less atom in the bridge linking the hydrophobic and carboxylic acid termini of the retinoid skeleton. Therefore, a one-carbon bridge replaces the 19-methyl group and 9E-double bond of 9-cis-retinoic acid and is further functionalized by inclusion in an isopropylidene group, a dioxolane ring, or a cyclopropane ring for optimal RXR alpha activity and selectivity. In addition, the beta-geranylidene and 20-methyl-(11E,13E)-dienoic acid groups of 9-cis-retinoic acid are replaced by a 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl ring and a 4-carboxylphenyl ring, respectively, for optimal activation and selectivity. RXR alpha selectivity is reduced on replacement of the 4-carboxylphenyl group by a 2-carboxyl-5-thienyl group or the 9-cis-retinoic acid methylpentadienoic acid terminus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650690     DOI: 10.1021/jm00017a021

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids.

Authors:  Q Wu; M I Dawson; Y Zheng; P D Hobbs; A Agadir; L Jong; Y Li; R Liu; B Lin; X K Zhang
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

2.  Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.

Authors:  Marcia I Dawson; Mao Ye; Xihua Cao; Lulu Farhana; Qiong-Ying Hu; Yong Zhao; Li Ping Xu; Alice Kiselyuk; Ricardo G Correa; Li Yang; Tingjun Hou; John C Reed; Pamela Itkin-Ansari; Fred Levine; Michel F Sanner; Joseph A Fontana; Xiao-Kun Zhang
Journal:  ChemMedChem       Date:  2009-07       Impact factor: 3.466

3.  Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.

Authors:  Philippe Diaz; Weize Huang; Charles M Keyari; Brian Buttrick; Lauren Price; Nicolas Guilloteau; Sasmita Tripathy; Vanessa G Sperandio; Frank R Fronczek; Fanny Astruc-Diaz; Nina Isoherranen
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

4.  Metabolism to a response pathway selective retinoid ligand during axial pattern formation.

Authors:  W W Pijnappel; G E Folkers; W J de Jonge; P J Verdegem; S W de Laat; J Lugtenburg; H F Hendriks; P T van der Saag; A J Durston
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway.

Authors:  H Y Lee; D F Dohi; Y H Kim; G L Walsh; U Consoli; M Andreeff; M I Dawson; W K Hong; J M Kurie
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

6.  Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor's oligomeric switch.

Authors:  Rubina Yasmin; Padmamalini Kannan-Thulasiraman; Hiroyuki Kagechika; Marcia I Dawson; Noa Noy
Journal:  J Mol Biol       Date:  2010-02-24       Impact factor: 5.469

7.  The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain.

Authors:  Jianyun Lu; Marcia I Dawson; Qiong Ying Hu; Zebin Xia; Jesse D Dambacher; Mao Ye; Xiao-Kun Zhang; Ellen Li
Journal:  Magn Reson Chem       Date:  2009-12       Impact factor: 2.447

8.  Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

Authors:  Julie K Furmick; Ichiro Kaneko; Angela N Walsh; Joanna Yang; Jaskaran S Bhogal; Geoffrey M Gray; Juan C Baso; Drew O Browder; Jessica L S Prentice; Luis A Montano; Chanh C Huynh; Lisa M Marcus; Dorian G Tsosie; Jungeun S Kwon; Alexis Quezada; Nicole M Reyes; Brittney Lemming; Puneet Saini; Arjan van der Vaart; Thomas L Groy; Pamela A Marshall; Peter W Jurutka; Carl E Wagner
Journal:  ChemMedChem       Date:  2012-09       Impact factor: 3.466

9.  Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

Authors:  Carl E Wagner; Peter W Jurutka; Pamela A Marshall; Thomas L Groy; Arjan van der Vaart; Joseph W Ziller; Julie K Furmick; Mark E Graeber; Erik Matro; Belinda V Miguel; Ivy T Tran; Jungeun Kwon; Jamie N Tedeschi; Shahram Moosavi; Amina Danishyar; Joshua S Philp; Reina O Khamees; Jevon N Jackson; Darci K Grupe; Syed L Badshah; Justin W Hart
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

10.  Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.

Authors:  Leeann J Boerma; Gang Xia; Cheng Qui; Bryan D Cox; Michael J Chalmers; Craig D Smith; Susan Lobo-Ruppert; Patrick R Griffin; Donald D Muccio; Matthew B Renfrow
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.